MRNA Stock Overview
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 5/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Moderna, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$121.89 |
52 Week High | US$142.79 |
52 Week Low | US$62.55 |
Beta | 1.59 |
1 Month Change | 15.99% |
3 Month Change | 30.14% |
1 Year Change | -6.83% |
3 Year Change | -20.17% |
5 Year Change | 427.21% |
Change since IPO | 555.32% |
Recent News & Updates
We Discuss Why Moderna, Inc.'s (NASDAQ:MRNA) CEO Compensation May Be Closely Reviewed
Apr 30Moderna, Inc.'s (NASDAQ:MRNA) Prospects Need A Boost To Lift Shares
Apr 22Moderna: Considering The Cancer Vaccine Angle
Apr 11Recent updates
We Discuss Why Moderna, Inc.'s (NASDAQ:MRNA) CEO Compensation May Be Closely Reviewed
Apr 30Moderna, Inc.'s (NASDAQ:MRNA) Prospects Need A Boost To Lift Shares
Apr 22Moderna: Considering The Cancer Vaccine Angle
Apr 11Moderna Continues To Build A Pipeline
Apr 03Lukewarm Reaction To Moderna's Vaccine Day Sums Up Fine Margins In Play
Mar 27Moderna, Inc. (NASDAQ:MRNA) Just Released Its Yearly Results And Analysts Are Updating Their Estimates
Feb 27Moderna: Counting On Pipeline Too Much
Feb 23Moderna: Highly Uncertain Future For mRNA Vaccine In A Post-Pandemic World
Feb 16Moderna: Fade 2025 Outlook
Jan 15Moderna, Inc. (NASDAQ:MRNA) Held Back By Insufficient Growth Even After Shares Climb 26%
Dec 29Need To Know: The Consensus Just Cut Its Moderna, Inc. (NASDAQ:MRNA) Estimates For 2024
Nov 03Moderna, Inc. (NASDAQ:MRNA) Shares Could Be 30% Below Their Intrinsic Value Estimate
Oct 18Is Moderna, Inc. (NASDAQ:MRNA) Trading At A 47% Discount?
May 23Shareholder Returns
MRNA | US Biotechs | US Market | |
---|---|---|---|
7D | 9.4% | 1.3% | 3.3% |
1Y | -6.8% | 3.0% | 25.0% |
Return vs Industry: MRNA underperformed the US Biotechs industry which returned 3% over the past year.
Return vs Market: MRNA underperformed the US Market which returned 25% over the past year.
Price Volatility
MRNA volatility | |
---|---|
MRNA Average Weekly Movement | 8.1% |
Biotechs Industry Average Movement | 11.4% |
Market Average Movement | 6.1% |
10% most volatile stocks in US Market | 16.5% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: MRNA's share price has been volatile over the past 3 months.
Volatility Over Time: MRNA's weekly volatility (8%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2010 | 5,600 | Stephane Bancel | www.modernatx.com |
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics.
Moderna, Inc. Fundamentals Summary
MRNA fundamental statistics | |
---|---|
Market cap | US$46.40b |
Earnings (TTM) | -US$5.97b |
Revenue (TTM) | US$5.15b |
9.1x
P/S Ratio-7.8x
P/E RatioIs MRNA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
MRNA income statement (TTM) | |
---|---|
Revenue | US$5.15b |
Cost of Revenue | US$8.77b |
Gross Profit | -US$3.62b |
Other Expenses | US$2.35b |
Earnings | -US$5.97b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -15.57 |
Gross Margin | -70.27% |
Net Profit Margin | -115.82% |
Debt/Equity Ratio | 0% |
How did MRNA perform over the long term?
See historical performance and comparison